索拉非尼联合卡培他滨治疗肝细胞肝癌的效果观察  

Observation of therapeutic effect of sorafenib combined with capecitabine on hepatocellular carcinoma

作　　者：王琳 马婕群 白杰 张彦兵 Wang Lin;Ma Jiequn;Bai Jie;Zhang Yanbing(Department of Clinical Pharmacy,Shaanxi Cancer Hospital,Xi'an 710061,China;Department of Oncology,Shaanxi Cancer Hospital,Xi'an 710061,China)

机构地区：[1]陕西省肿瘤医院临床药学室,西安710061 [2]陕西省肿瘤医院肿瘤内科,西安710061

出　　处：《中国实用医刊》2024年第16期89-92,共4页Chinese Journal of Practical Medicine

基　　金：陕西省重点研发计划项目(2021SF-220)。

摘　　要：目的探讨索拉非尼联合卡培他滨治疗肝细胞肝癌(HCC)的效果。方法回顾性抽取2020年10月至2023年10月陕西省肿瘤医院收治的88例HCC患者,按治疗方案分为对照组和研究组,每组44例。对照组采用索拉非尼治疗,研究组采用索拉非尼、卡培他滨联合治疗。比较两组疾病控制率,比较两组治疗前后肝功能指标[总胆红素(TBIL)、丙氨酸转氨酶(ALT)]、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)]水平,比较两组不良反应发生情况。结果研究组疾病控制率(84.41%,37/44)高于对照组(59.09%,26/44),P<0.05。治疗2、4个周期后,研究组TBIL、ALT水平低于对照组(P<0.05),AFP、CEA水平低于对照组(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论索拉非尼、卡培他滨联合治疗HCC,可有效抑制肿瘤标志物释放,减轻肝功能损伤,提升疗效,且不良反应较少。Objective To investigate the efficacy of sorafenib combined with capecitabine in the treatment of hepatocellular carcinoma(HCC).Methods Eighty-eight HCC patients admitted to Shaanxi Cancer Hospital from October 2020 to October 2023 were retrospectively selected,and they were divided into a control group and a study group according to the treatment plan,with 44 cases in each group.The control group was treated with sorafenib,while the study group was treated with sorafenib combined with capecitabine.The disease control rates of the two groups were compared.The liver function indicators including total bilirubin(TBIL)and alanine transaminase(ALT),tumor markers includingα-fetoprotein(AFP)and carcinoembryonic antigen(CEA)of the two groups were compared before and after treatment.The incidence of adverse reactions were compared between the two groups.Results The disease control rate of the study group(84.41%,37/44)was higher than that of the control group(59.09%,26/44),P<0.05.The levels of TBIL and ALT in the study group were lower than those in the control group after 2 and 4 cycles of treatment(P<0.05).After 2 and 4 cycles of treatment,the levels of AFP and CEA in the study group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions The combination of sorafenib and capecitabine can effectively inhibit the expression of tumor markers in HCC patients,reduce liver function injury,improve efficacy,and reduce adverse reactions.

关 键 词：肝细胞肝癌 索拉非尼 卡培他滨 肝功能 肿瘤标志物 

分 类 号：R735.7[医药卫生—肿瘤]